Long-term results of intensified, n-terminal-pro-b-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure five-year follow-up from TIME-CHF

Circulation: Heart Failure

Volumn 7, Issue 1, 2014, Pages 131-139

  Wijk, Sandra Sanders Van ^a   Maeder, Micha T ^b   Nietlispach, Fabian ^c   Rickli, Hans ^b   Estlinbaum, Werner ^d   Erne, Paul ^b   Rickenbacher, Peter ^e   Peter, Martin ^b   Pfisterer, Matthias P ^f   Brunner La Rocca, Hans Peter ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Cardiology Kantonsspital St Gallen ^*  (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Kantonsspital Liestal   (Switzerland)

^e University Hospital Bruderholz   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Aging; Heart failure; Pro brain natriuretic peptide (1 76); Prognosis; Type B natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; COMORBIDITY; ELDERLY CARE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGING; HEART FAILURE; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROGNOSIS; TYPE-B NATRIURETIC PEPTIDE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DISEASE MANAGEMENT; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; SURVIVAL RATE; SYMPTOM ASSESSMENT;

EID: 84896124420     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000527     Document Type: Article

References (36)

1. Felker GM, Hasselblad V, Hernandez AF, O?Connor CM. Biomarker- guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422-430.
2. Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, Afzal R, White M, Nordmann AJ. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One. 2010;5:e9946.
3. Li P, Luo Y, Chen YM. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ. 2013;22:852-860.
4. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8:e58287.
5. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
6. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-1739.
7. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP; TIME- CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383-392.
8. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro- B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55:53-60.
9. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12:1300-1308.
10. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56:2090-2100.
11. Anguita M, Esteban F, Castillo JC, Mazuelos F, López-Granados A, Arizón JM, Suárez De Lezo J. [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure]. Med Clin (Barc). 2010;135:435-440.
12. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55:645-653.
13. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, Fiuzat M, Stevenson LW, O?Connor CM. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail. 2011;17:613-621.
14. Karlström P, Alehagen U, Boman K, Dahlström U; UPSTEP-Study Group. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail. 2011;13:1096-1103.
15. Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881-1889.
16. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck- Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (hfa) of the esc. Eur Heart J.. 2012;14:803-869.
17. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-1739.
18. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M. Management of elderly patients with congestive heart failure-design of the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (time-chf). Am Heart J.. 2006;151:949-955.
19. Rickenbacher P, Pfisterer M, Burkard T, Kiowski W, Follath F, Burckhardt D, Schindler R, Brunner-La Rocca HP; TIME-CHF Investigators. Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail. 2012;14:1218-1229.
20. Hülsmann M, Berger R, Mörtl D, Pacher R. Influence of age and in- patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey. Eur J Heart Fail. 2005;7:657-661.
21. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R; Midlands Research Practices Consortium (MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J. 2007;28:1128-1134.
22. Karlström P, Alehagen U, Boman K, Dahlström U; UPSTEP-study group. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail. 2011;13:1096-1103.
23. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure-SIGNAL-HF (Swedish Intervention Study-guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12:1300-1308.
24. A Service of the U.S. National Institutes of Health. Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT). http://clinicaltrials.gov/ct2/show/NCT01685840?term=guide+it&rank=1.
25. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O?Connor CM, Pieper K, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70.
26. Gheorghiade M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, Mehra MR, O?Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail. 2012;18:9-17.
27. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen- Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464-474.
28. Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, Porcu M, Scherillo M, Opasich C, Di Lenarda A, Senni M, Maggioni AP; IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J. 2002;143:45-55.
29. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O?Connor CM, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J. 2009;157:754-62.e2.
30. Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M; French National College of Cardiologists. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey. Arch Cardiovasc Dis. 2012;105:355-365.
31. Ambrosy AP, Fonarow GC, Albert NM, Curtis AB, Heywood JT, Mehra MR, O?Connor CM, Reynolds D, Walsh MN, Yancy CW, Gheorghiade M. B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. J Cardiovasc Med (Hagerstown). 2012;13:360-367.
32. Lorgis L, Zeller M, Dentan G, Sicard P, Buffet P, L?Huillier I, Beer JC, Vincent-Martin M, Makki H, Gambert P, Cottin Y; RICO Survey Working Group. Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. BMJ. 2009;338:b1605.
33. Burger PC, Brunner-La Rocca H. Pharmacotherapy of congestive heart failure in elderly patients. J Cardiovasc Pharmacol Ther. 2005;10:85-94.
34. Cheng JW, Nayar M. A review of heart failure management in the elderly population. Am J Geriatr Pharmacother. 2009;7:233-249.
35. Arif SA, Mergenhagen KA, Del Carpio RO, Ho C. Treatment of systolic heart failure in the elderly: an evidence-based review. Ann Pharmacother. 2010;44:1604-1614.
36. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363-371.